1
|
Alaizeri ZM, Alhadlaq HA, Aldawood S, Javed Akhtar M, Ahamed M. One-step preparation, characterization, and anticancer potential of ZnFe 2O 4/RGO nanocomposites. Saudi Pharm J 2023; 31:101735. [PMID: 37638224 PMCID: PMC10448167 DOI: 10.1016/j.jsps.2023.101735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Accepted: 07/30/2023] [Indexed: 08/29/2023] Open
Abstract
Zinc ferrite nanoparticles (ZnFe2O4 NPs) have attracted extensive attention for their diverse applications including sensing, waste-water treatment, and biomedicine. The novelty of the present work is the fabrication of ZnFe2O4/RGO NCs by using a one-step hydrothermal process to assess the influence of RGO doping on the physicochemical properties and anticancer efficacy of ZnFe2O4 NPs. X-ray diffraction (XRD), Scanning electron microscopy (SEM), Energy-dispersive X-ray(EDX), X-ray photoelectron spectroscopy (XPS), Fourier-transform infrared spectroscopy (FTIR), UV-vis spectroscopy, and Photoluminescence (PL) spectroscopy were employed to characterize prepared pure ZnFe2O4 NPs and ZnFe2O4/ RGO NCs. XRD results showed that the synthesized samples have high crystallinity. Furthermore, the average crystal sizes of ZnFe2O4 nanoparticles (NPs) and ZnFe2O4/RGO nanocomposites (NCs) were 51.08 nm and 54.36 nm, respectively. SEM images revealed that pure ZnFe2O4 NPs were spherical in shape with uniformly loaded on the surface of the RGO nanosheet. XPS and EDX analysis confirmed the elemental compositions of ZnFe2O4/RGO NCs. Elemental mapping of SEM shows that the elemental compositions (Zn, Fe, O, and C) were homogeneously distributed in ZnFe2O4/RGO NCs. The intensity of FT-IR spectra depicted that pure ZnFe2O4 NPs were successfully anchored into the RGO nanosheet. An optical study suggested that the band gap energy of ZnFe2O4/RGO NCs (1.61 eV) was lower than that of pure ZnFe2O4 NPs (1.96 eV). PL spectra indicated that the recombination rate of the ZnFe2O4/ RGO NCs was lower than ZnFe2O4 NPs. MTT assay was used to evaluate the anticancer performance of ZnFe2O4 /RGO NCs and pure ZnFe2O4NPs against human cancer cells. In vitro study indicates that ZnFe2O4 /RGO NCs have higher anticancer activity against human breast (MCF-7) and lung (A549) cancer cells as compared to pure form ZnFe2O4 NPs. This work suggests that RGO doping enhances the anticancer activity of ZnFe2O4NPs by tuning its optical behavior. This study warrants future research on potential therapeutic applications of these types of nanocomposites.
Collapse
Affiliation(s)
- ZabnAllah M. Alaizeri
- Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Hisham A. Alhadlaq
- Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Saad Aldawood
- Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Mohd Javed Akhtar
- Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| | - Maqusood Ahamed
- Department of Physics and Astronomy, College of Science, King Saud University, Riyadh 11451, Saudi Arabia
| |
Collapse
|
2
|
Mushtaq A, Li L, A A, Grøndahl L. Chitosan Nanomedicine in Cancer Therapy: Targeted Delivery and Cellular Uptake. Macromol Biosci 2021; 21:e2100005. [PMID: 33738977 DOI: 10.1002/mabi.202100005] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2021] [Revised: 02/22/2021] [Indexed: 12/11/2022]
Abstract
Nanomedicine has gained much attention for the management and treatment of cancers due to the distinctive physicochemical properties of the drug-loaded particles. Chitosan's cationic nature is attractive for the development of such particles for drug delivery, transfection, and controlled release. The particle properties can be improved by modification of the polymer or the particle themselves. The physicochemical properties of chitosan particles are analyzed in 126 recent studies, which allows to highlight their impact on passive and active targeted drug delivery, cellular uptake, and tumor growth inhibition (TGI). From 2012 to 2019, out of 40 in vivo studies, only 4 studies are found reporting a reduction in tumor size by using chitosan particles while all other studies reported tumor growth inhibition relative to controls. A total of 23 studies are analyzed for cellular uptake including 12 studies reporting cellular uptake mechanisms. Understanding and exploiting the processes involved in targeted delivery, endocytosis, and exocytosis by controlling the physicochemical properties of chitosan particles are important for the development of safe and efficient nanomedicine. It is concluded based on the recent literature available on chitosan particles that combination therapies can play a pivotal role in transformation of chitosan nanomedicine from bench to bedside.
Collapse
Affiliation(s)
- Asim Mushtaq
- School of Chemistry and Molecular Biosciences, The University of Queensland, Building 68, Cooper Road, Brisbane, Queensland, 4072, Australia
| | - Li Li
- Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 75, Corner of College and Cooper Road, Brisbane, Queensland, 4072, Australia
| | - Anitha A
- School of Chemistry and Molecular Biosciences, The University of Queensland, Building 68, Cooper Road, Brisbane, Queensland, 4072, Australia
| | - Lisbeth Grøndahl
- School of Chemistry and Molecular Biosciences, The University of Queensland, Building 68, Cooper Road, Brisbane, Queensland, 4072, Australia.,Australian Institute for Bioengineering and Nanotechnology, The University of Queensland, Building 75, Corner of College and Cooper Road, Brisbane, Queensland, 4072, Australia
| |
Collapse
|
3
|
Martín MJ, Gentili C, Lassalle V. In vitro Biological Tests as the First Tools To Validate Magnetic Nanotheranostics for Colorectal Cancer Models. ChemMedChem 2020; 15:1003-1017. [PMID: 32365271 DOI: 10.1002/cmdc.202000119] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2020] [Revised: 05/03/2020] [Indexed: 12/13/2022]
Abstract
Colorectal cancer (CRC) remains a leading cause of cancer death. Nanotechnology has focused on reaching more effective treatments. In this concern, magnetic nanoparticles (MNPs) have been studied for a wide range of biomedical applications related to CRC, such as diagnostic imaging, drug delivery and thermal therapy. However, limited research is currently found in the open literature that refers to nanosystems combining all these mentioned areas (theranostics). When developing nanosystems intended as theranostics applied to CRC, possible variations between patients must be considered. Therefore, multiple in vitro assays are required as guidance for future preclinical and clinical trials. The objective of this contribution is to evaluate the available and recent literature regarding the interactions of MNP and CRC models, aiming to critically analyze the information given by the commonly used assays and evaluate the data provided by each one with a view to implementing this novel technology in CRC diagnostics and therapy.
Collapse
Affiliation(s)
- María Julia Martín
- INQUISUR, Departamento de Química, Universidad Nacional del Sur (CONICET-UNS), Alem 1253, Bahía Blanca, Argentina.,INBIOSUR, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (CONICET-UNS), San Juan 670, Bahía Blanca, Argentina
| | - Claudia Gentili
- INBIOSUR, Departamento de Biología, Bioquímica y Farmacia, Universidad Nacional del Sur (CONICET-UNS), San Juan 670, Bahía Blanca, Argentina
| | - Verónica Lassalle
- INQUISUR, Departamento de Química, Universidad Nacional del Sur (CONICET-UNS), Alem 1253, Bahía Blanca, Argentina
| |
Collapse
|
4
|
Massoumi B, Taghavi N, Ghamkhari A. Synthesis of a new biodegradable system based on β-cyclodextrin/iron oxide nanocomposite: application for delivery of docetaxel. Polym Bull (Berl) 2020. [DOI: 10.1007/s00289-020-03254-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
|
5
|
Salvanou EA, Stellas D, Tsoukalas C, Mavroidi B, Paravatou-Petsotas M, Kalogeropoulos N, Xanthopoulos S, Denat F, Laurent G, Bazzi R, Roux S, Bouziotis P. A Proof-of-Concept Study on the Therapeutic Potential of Au Nanoparticles Radiolabeled with the Alpha-Emitter Actinium-225. Pharmaceutics 2020; 12:pharmaceutics12020188. [PMID: 32098286 PMCID: PMC7076693 DOI: 10.3390/pharmaceutics12020188] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Revised: 01/20/2020] [Accepted: 02/19/2020] [Indexed: 01/01/2023] Open
Abstract
Actinium-225 (225Ac) is receiving increased attention for its application in targeted radionuclide therapy, due to the short range of its emitted alpha particles in conjunction with their high linear energy transfer, which lead to the eradication of tumor cells while sparing neighboring healthy tissue. The objective of our study was the evaluation of a gold nanoparticle radiolabeled with 225Ac as an injectable radiopharmaceutical form of brachytherapy for local radiation treatment of cancer. Au@TADOTAGA was radiolabeled with 225Ac at pH 5.6 (30 min at 70 °C), and in vitro stability was evaluated. In vitro cytotoxicity was assessed in U-87 MG cancer cells, and in vivo biodistribution was performed by intravenous and intratumoral administration of [225Ac]225Ac-Au@TADOTAGA in U-87 MG tumor-bearing mice. A preliminary study to assess therapeutic efficacy of the intratumorally-injected radio-nanomedicine was performed over a period of 22 days, while the necrotic effect on tumors was evaluated by a histopathology study. We have shown that [225Ac]225Ac-Au@TADOTAGA resulted in the retardation of tumor growth after its intratumoral injection in U87MG tumor-bearing mice, even though very low activities were injected per mouse. This gold nanoparticle radiopharmaceutical could be applied as an unconventional brachytherapy in injectable form for local radiation treatment of cancer.
Collapse
Affiliation(s)
- Evangelia-Alexandra Salvanou
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.T.); (M.P.-P.); (S.X.)
| | - Dimitris Stellas
- Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece
| | - Charalampos Tsoukalas
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.T.); (M.P.-P.); (S.X.)
| | - Barbara Mavroidi
- Institute of Biosciences and Applications, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece;
| | - Maria Paravatou-Petsotas
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.T.); (M.P.-P.); (S.X.)
| | | | - Stavros Xanthopoulos
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.T.); (M.P.-P.); (S.X.)
| | - Franck Denat
- ICMUB, UMR 6302 CNRS-UB, Université Bourgogne Franche-Comté, 21000 Dijon, France;
| | - Gautier Laurent
- Institut UTINAM, UMR 6213 CNRS-UBFC, Université Bourgogne Franche-Comté, 25030 Besançon, France; (G.L.); (R.B.); (S.R.)
| | - Rana Bazzi
- Institut UTINAM, UMR 6213 CNRS-UBFC, Université Bourgogne Franche-Comté, 25030 Besançon, France; (G.L.); (R.B.); (S.R.)
| | - Stephane Roux
- Institut UTINAM, UMR 6213 CNRS-UBFC, Université Bourgogne Franche-Comté, 25030 Besançon, France; (G.L.); (R.B.); (S.R.)
| | - Penelope Bouziotis
- Institute of Nuclear & Radiological Sciences & Technology, Energy & Safety, National Center for Scientific Research “Demokritos”, 15341 Athens, Greece; (E.-A.S.); (C.T.); (M.P.-P.); (S.X.)
- Correspondence: ; Tel.: +30-21-0650-3687
| |
Collapse
|